ResApp (ASX:RAP) share price jumps 5% on regulatory approval

What did ResApp announce?

| More on:
A businessman leaps in the air outside a city building in the CBD.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResApp Health Ltd (ASX: RAP) share price ticked up a notch towards the end of Monday's market session. This followed the digital health company's announcement that it has secured regulatory approval for its cough counter smartphone application.

At the closing bell, ResApp shares ended the day 5.36% higher to 5.9 cents apiece.

ResApp receives TGA clearance for cough counter smartphone application

Investors appeared to be excited by the company's latest news, sending the ResApp share price into positive territory.

In the release, ResApp advised that its cough counter smartphone application has been approved by the Australian Therapeutics Good Administration (TGA). In addition, the medical software has also achieved a CE Mark certification.

The significant milestone enables ResApp to sell its cough counter smartphone application in Europe as a class 1 medical device. The software is also listed on the Australian Register of Therapeutic Goods (ARTG).

Notably, ResApp now holds the title of being the world's first regulatory-approved standalone cough counter smartphone application.

Developed over the last 12 months, the cough counting application is designed to identify coughs and background noises in everyday settings. The software records the number of coughs from the user and uploads the data in a form of time and date stamps. This is then accessible to medical and healthcare professionals to monitor in real-time.

The company noted that cough frequency is a key factor in respiratory disease progression and management. Traditional methods such as self-reporting or listening to audio recordings are said to be costly that are inaccurate and labour-intensive.

The software is already being used by AstraZeneca in a clinical study to monitor patients who suffer from lung cancer. The program is set to run for a period of two years.

Management commentary

ResApp CEO and managing director, Dr Tony Keating said:

We are pleased to have secured regulatory clearance in Australia and Europe for our cough counting technology. The ability to measure cough frequency using only a smartphone is a highly scalable solution that has a number of broad clinical applications. After our success in partnering with AstraZeneca, we are particularly excited about the opportunity in supporting clinical trials, where cough can provide important insight into the progression of disease and efficacy of treatment.

ResApp share price summary

In July, ResApp shares were trading at multi-year lows before shooting up in the following months. While the company's shares are down 30% year to date, the past week alone has netted a gain of almost 10%.

ResApp commands a market capitalisation of about $50.69 million and has 859.2 million shares on its books.

Motley Fool contributor Aaron Teboneras has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

This bombshell for ASX healthcare shares could hit 6 million Australians

This could have a large impact.

Read more »

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.
Healthcare Shares

2 ASX healthcare shares having a stellar run today

The ASX healthcare sector is down today but these two stocks are bucking the trend.

Read more »

A company manager presents the ASX company earnings report to shareholders at an AGM.
Healthcare Shares

Why this $13 billion ASX 200 healthcare stock is surging today

A change in sentiment for the healthcare player.

Read more »

Shot of a scientist using a computer while conducting research in a laboratory.
Healthcare Shares

This ASX 200 stock hit a 52-week low and a top broker thinks it can rebound

Patient investors may see this stock make a pleasing recovery.

Read more »

A couple smile as they look at a pregnancy test.
Healthcare Shares

Why this sold-off ASX healthcare share could be an exciting dividend buy

This could be a healthy stock for dividends.

Read more »

a smiling woman sits at her computer at home with a coffee alongside her, as if pleased with her investments.
Healthcare Shares

Is CSL the best ASX 100 share to buy now?

Bell Potter has good things to say about this blue chip star.

Read more »

Scientists in a laboratory look at a computer screen with anticipation on their faces representing a potential change in the performance of ASX biotech shares in FY23
Healthcare Shares

Down 10% in a month, are CSL shares feeling the sting of a potential disruption?

Brokers are still bullish.

Read more »

One girl leapfrogs over her friend's back.
Healthcare Shares

Doubled in a year! Does this booming ASX share have another 24% upside?

Let's take a look.

Read more »